Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
[hodgkin lymphoma, classical]
Due
to
disease
rarity
,
there
is
limited
information
regarding
the
optimal
therapy
and
outcome
for
patients
with
advanced
-
stage
nodular
lymphocyte-predominant
Hodgkin
lymphoma
(
NLPHL
)
.
Forty
-
two
patients
with
NLPHL
by
the
Revised
European-
American
Lymphoma
/
World
Health
Organization
classification
with
advanced
-
stage
disease
were
identified
and
paired
1
:
2
with
a
matched
control
with
classical
Hodgkin
lymphoma
(
CHL
)
matched
by
age
,
gender
,
stage
,
decade
of
diagnosis
,
and
treatment
received
.
The
median
follow-up
was
11
.
3
years
(
range
,
1
.
9
to
35
.
5
years
)
for
NLPHL
patients
and
10
.
7
years
(
range
,
1
.
6
to
26
.
3
years
)
for
CHL
patients
.
The
majority
received
doxorubicin
,
bleomycin
,
vinblastine
,
and
dacarbazine
(
ABVD
)
-
like
chemotherapy
.
Although
the
10
-
year
overall
survival
(
OS
)
(
P
=
.
579
)
and
HL
freedom
from
treatment
failure
(
HL-FFTF
)
were
similar
between
NLPHL
and
CHL
patients
(
75
%
vs
73
%
;
P
=
.
610
)
,
the
time
to
progression
(
TTP
)
,
which
also
includes
the
development
of
secondary
aggressive
lymphoma
,
was
inferior
in
NLPHL
(
10
-
year
,
63
%
vs
73
%
;
P
=
.
040
)
.
Splenic
involvement
was
associated
with
an
inferior
10
-
year
TTP
in
patients
treated
with
ABVD
(
48
%
vs
71
%
;
P
=
.
049
)
and
an
increased
cumulative
incidence
of
secondary
aggressive
lymphoma
(
P
=
.
014
)
providing
a
rationale
for
further
evaluation
of
cyclophosphamide
,
doxorubicin
,
vincristine
,
and
prednisone
(
CHOP
)
with
rituximab
in
NLPHL
.
Diseases
Validation
Diseases presenting
"matched control with classical hodgkin lymphoma"
symptom
hodgkin lymphoma, classical
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom